As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

 4/29/24  Addex Therapeutics Ltd.           6-K         4/29/24    2:16K                                    Globenewswire Inc./FA    
 4/24/24  Addex Therapeutics Ltd.           424B3                  1:1.3M                                   Toppan Merrill/FA        
 4/22/24‡ Addex Therapeutics Ltd.           EFFECT      4/22/24    1:2K                                     SEC #5                   
 4/18/24  Addex Therapeutics Ltd.           POS AM                 2:1.4M                                   Toppan Merrill/FA        
 4/18/24  Addex Therapeutics Ltd.           20-F       12/31/23  118:15M                                    Toppan Merrill/FA        
 4/18/24  Addex Therapeutics Ltd.           6-K         4/18/24    2:23K                                    Globenewswire Inc./FA    
  4/3/24  Addex Therapeutics Ltd.           6-K          4/3/24    2:19K                                    Globenewswire Inc./FA    
 1/30/24  Addex Therapeutics Ltd.           424B5                  1:1M                                     Toppan Merrill/FA        
 1/30/24  Addex Therapeutics Ltd.           6-K         1/30/24    3:269K                                   Toppan Merrill/FA        
12/21/23  Addex Therapeutics Ltd.           6-K/A       6/30/23   76:6.3M                                   Toppan Merrill/FA        
12/20/23  Addex Therapeutics Ltd.           6-K        12/20/23    2:13K                                    Globenewswire Inc./FA    
12/14/23  Addex Therapeutics Ltd.           6-K        12/14/23    2:14K                                    Globenewswire Inc./FA    
 12/8/23  Growth Equity Opportuniti… IV LLC SC 13D/A               1:274K Addex Therapeutics Ltd.           Go2 EDGAR SOLUTIONS… /FA 
          Anthony A. Florence, Jr.³
          Forest Baskett³
          Mohamad H. Makhzoumi³
          Nea 15 GP, LLC³
          NEA Partners 15, L.P.³
          New Enterprise Associates 15, L.P.³
          Scott D. Sandell³
11/30/23  Addex Therapeutics Ltd.           424B3                  1:443K                                   Toppan Merrill/FA        
11/29/23‡ Addex Therapeutics Ltd.           EFFECT     11/29/23    1:2K                                     SEC #5                   
11/29/23  Dyer Timothy Mark                 SC 13D/A               1:57K  Addex Therapeutics Ltd.           Toppan Merrill/FA        
11/29/23  Addex Therapeutics Ltd.           POS AM                 2:542K                                   Toppan Merrill/FA        
11/29/23  Addex Therapeutics Ltd.           6-K        11/29/23    4:1.1M                                   Toppan Merrill/FA        
11/28/23  Addex Therapeutics Ltd.           6-K        11/28/23    2:13K                                    Globenewswire Inc./FA    
11/14/23  Addex Therapeutics Ltd.           6-K        11/14/23    2:17K                                    Globenewswire Inc./FA    

____________
‡	A non-Insider-Ownership Filing that was accepted after the SEC “closed” at 5:30:00pm ET.  The legal “Filed As Of” date may be the next, or another, day.
¹	Filing/Form Types:
	6-K	Current, Quarterly or Annual Report by a Foreign Issuer — Form 6-K.
	20-F	Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer — Form 20-F.
	424B3	Prospectus – New Facts or Events.
	424B5	Prospectus – Primary Offering or Shelf Securities – New Facts or Events.
	EFFECT	SEC Notice of Effectiveness.
	POS AM	Post-Effective Amendment of a Registration Statement.
	SC 13D	Statement of Acquisition of Beneficial Ownership by an “Active” Investor — Schedule 13D.
	/A	Amendment to, or Amended version of, a previous Filing of this Type.
³	Group Member:  A Registrant or non-Registrant party to this Filing made by a Group.